Heron Patrick J's Form 4 filing
Mirum Pharmaceuticals, Inc. (MIRM) · filed Jan 27, 2026
- Accession no.
- 0001365617-26-000002
- Filed
- Jan 27, 2026
- Trade date
- Jan 23, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $9.00M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Heron Patrick JCIK 0001365617 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2026 | Common Stock | JOtherAcquired | +159,277 | –F1 | – | 327,585 | Indirect | |
| Jan 23, 2026 | Common Stock | PPurchaseAcquired | +131,425 | $68.48 | +$8,999,984 | 459,010 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Frazier Life Sciences X, L.P. received these shares in connection with merger of Bluejay Therapeutics, Inc. into the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's Common Stock was $94.29 per share.
Referenced by the price of 1 transaction in Table I.